Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 27 04 2018
accepted: 28 06 2018
pubmed: 10 7 2018
medline: 15 11 2019
entrez: 9 7 2018
Statut: ppublish

Résumé

Since the emergence of influenza A(H7N9) virus in 2013, there have been 5 waves of influenza A(H7N9) epidemics in China. However, evolution of the hemagglutinin (HA) protein antigenicity has not been systematically investigated. To better understand how antigenic drift in HA proteins of influenza (A)H7N9 virus occurs, 902 influenza A(H7N9) virus HA protein sequences from a public database were retrieved and analyzed. Fifty-three mutants with single amino acid substitutions in HA protein were introduced into pseudoviruses, and their antigenic characteristics were analyzed using pseudovirus-based assays. The frequencies of 9 mutations incrementally increased over the past 5 years, with mutations identified at multiple sites. While mean neutralization titers of most variants remained unchanged, 3 mutations, A143V, A143T, and R148K, displayed a median 4-fold lower susceptibility to neutralization by antisera against influenza A/Anhui/1/2013(H7N9) virus. Notably, A143V and A143T were located outside the previously reported antigenic sites. The most dominant variant (A143V/R148K) in the most recent season constituted 74.11% of all mutations and demonstrated a 10-fold reduction in its reactivity to influenza A/Anhui/1/2013(H7N9) virus antisera. Importantly, compared with the DNA construct without the corresponding HA protein mutation, DNA vaccine encoding the A143V/R148K mutant induced a 5-fold increase in the neutralizing activity against this circulating virus. An appropriate vaccine strain should be considered in response to increasing antigenic drift in influenza A(H7N9) virus HA protein.

Sections du résumé

Background
Since the emergence of influenza A(H7N9) virus in 2013, there have been 5 waves of influenza A(H7N9) epidemics in China. However, evolution of the hemagglutinin (HA) protein antigenicity has not been systematically investigated.
Methods
To better understand how antigenic drift in HA proteins of influenza (A)H7N9 virus occurs, 902 influenza A(H7N9) virus HA protein sequences from a public database were retrieved and analyzed. Fifty-three mutants with single amino acid substitutions in HA protein were introduced into pseudoviruses, and their antigenic characteristics were analyzed using pseudovirus-based assays.
Results
The frequencies of 9 mutations incrementally increased over the past 5 years, with mutations identified at multiple sites. While mean neutralization titers of most variants remained unchanged, 3 mutations, A143V, A143T, and R148K, displayed a median 4-fold lower susceptibility to neutralization by antisera against influenza A/Anhui/1/2013(H7N9) virus. Notably, A143V and A143T were located outside the previously reported antigenic sites. The most dominant variant (A143V/R148K) in the most recent season constituted 74.11% of all mutations and demonstrated a 10-fold reduction in its reactivity to influenza A/Anhui/1/2013(H7N9) virus antisera. Importantly, compared with the DNA construct without the corresponding HA protein mutation, DNA vaccine encoding the A143V/R148K mutant induced a 5-fold increase in the neutralizing activity against this circulating virus.
Conclusions
An appropriate vaccine strain should be considered in response to increasing antigenic drift in influenza A(H7N9) virus HA protein.

Identifiants

pubmed: 29982588
pii: 5049177
doi: 10.1093/infdis/jiy408
doi:

Substances chimiques

Antigens, Viral 0
Hemagglutinin Glycoproteins, Influenza Virus 0
Influenza Vaccines 0
Vaccines, DNA 0
Neuraminidase EC 3.2.1.18

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-25

Commentaires et corrections

Type : CommentIn

Auteurs

Tingting Ning (T)

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing, China.
Graduate School of Peking Union Medical College, Beijing, China.

Jianhui Nie (J)

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing, China.

Weijin Huang (W)

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing, China.

Changgui Li (C)

Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.

Xuguang Li (X)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada.

Qiang Liu (Q)

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing, China.

Hui Zhao (H)

Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.

Youchun Wang (Y)

Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing, China.
Graduate School of Peking Union Medical College, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH